Insider Selling: SiBone (NASDAQ:SIBN) SVP Sells 3,329 Shares of Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,329 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $15.64, for a total value of $52,065.56. Following the completion of the sale, the senior vice president directly owned 258,352 shares of the company’s stock, valued at $4,040,625.28. The trade was a 1.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Stock Performance

Shares of SIBN stock opened at $16.39 on Friday. The stock has a fifty day moving average of $17.06 and a 200 day moving average of $16.54. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The firm has a market capitalization of $707.06 million, a price-to-earnings ratio of -29.27 and a beta of 0.91. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. SiBone has set its FY 2025 guidance at EPS. As a group, research analysts expect that SiBone will post -0.78 earnings per share for the current year.

Institutional Trading of SiBone

A number of large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of SiBone by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company’s stock valued at $328,000 after purchasing an additional 988 shares during the last quarter. Invesco Ltd. boosted its holdings in SiBone by 8.9% during the 4th quarter. Invesco Ltd. now owns 17,203 shares of the company’s stock valued at $241,000 after acquiring an additional 1,413 shares during the period. Rhumbline Advisers boosted its holdings in SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock valued at $838,000 after acquiring an additional 2,100 shares during the period. ANTIPODES PARTNERS Ltd purchased a new position in SiBone during the 1st quarter valued at $34,000. Finally, Barclays PLC lifted its holdings in shares of SiBone by 2.7% in the 4th quarter. Barclays PLC now owns 99,212 shares of the company’s stock worth $1,391,000 after buying an additional 2,589 shares during the period. Institutional investors own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SIBN shares. Cantor Fitzgerald set a $25.00 price objective on SiBone and gave the stock an “overweight” rating in a report on Monday, August 11th. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Needham & Company LLC restated a “buy” rating and set a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th. Finally, Truist Financial increased their price objective on SiBone from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $23.67.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.